Qiming Venture Partners Portfolio Companies Xiaomi, TianWu Technology, Biren Technology, and Galaxy Universal Named to World Artificial Intelligence Conference SAIL Award Top 30 List
The Superior AI Leader (SAIL) Award stands as a high-caliber, international honor in the global artificial intelligence community. Committed to the principle of "pursuing excellence, leading the future," it identifies world-leading AI projects that command broad recognition and esteem while advancing human welfare. The award aims to drive breakthroughs in technology, innovation in application, and exploration in governance — guiding the transformation toward intelligent progress.
Recently, the World Artificial Intelligence Conference (WAIC) SAIL Award Top 30 list was officially announced. The SAIL Award, short for Superior AI Influential Leader, stands as a prestigious, internationally recognized honor in the global AI community. Guided by the principle of "pursuing excellence and leading the future," it identifies world-leading AI projects that command broad recognition and acclaim while advancing human welfare. The award aims to drive technological breakthroughs, application innovation, and governance exploration — steering the transformation toward intelligent futures.
Qiming Venture Partners portfolio companies Xiaomi (01810.HK), Tiwee Biotechnology, Biren Technology, and Galaxy Universal have all been named to the SAIL Award Top 30 list.
Xiaomi
(Xiaomi HyperAI: A large-model intelligent engine for the full "human × car × home" ecosystem)
Tiwee Biotechnology
(AI-powered metabolic pathway design platform for protein function prediction and interaction)
Biren Technology
(Distributed OCS all-optical interconnect chip and supernode application innovation)
Galaxy Universal
(VLA embodied intelligence large model pre-trained entirely on synthetic data)
Named to the SAIL Award Top 30 List
The SAIL Award is built on four pillars: Superior, Applicative, Innovative, and Leading. With a vision of "reconstructing the paradigm of human social development through intelligent technology," it identifies benchmark "Intelligence+" projects for the information age. "SAIL" also evokes the image of setting sail — a hope that AI's wind-filled canvas will carry us toward a brighter future.
Source | World Artificial Intelligence Conference
2025 Qiming Venture Partners · Entrepreneurship and Investment Forum
Venture Capital Enters a Resonance Cycle of AI Technology and Applications
Coming July 28 during WAIC
Registration will open soon — stay tuned
Past Coverage
Qiming Stars | Three Qiming Venture Partners Portfolio Companies Named to WAIC SAIL Award Top 30 Qiming Honors | Qiming Venture Partners and Investors Named to 36Kr 2025 China Equity Investment Annual Rankings Qiming Perspectives | Alex Zhou: 2025 Will Be the Year AI Applications Go Mainstream
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has backed more than 580 high-growth innovative companies. Over 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. More than 80 have become recognized unicorns or super-unicorns.
Many Qiming portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Genrix Bio (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, and Biren Technology.